Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05899764 · ClinicalTrials.gov registry record · Phase 1
Epileptic Hippocampus in Alzheimer's Disease
A Phase 1 study, sponsored by University of California, Los Angeles.
- Not yet
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT05899764 is a Phase 1 study that has not yet begun recruiting, run by University of California, Los Angeles. The registered enrollment target is 25 participants.
The verdict
NCT05899764, a Phase 1 study, has not yet begun recruiting, sponsored by University of California, Los Angeles.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The major goals of the study are to 1) characterize hippocampal activity in patients with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and AD who have suspected hippocampal epileptic activity based on scalp EEG recordings from IRB # 21-001603; 2) study the efficacy of brivaracetam to suppress epileptic activity and pathological high frequency oscilations (pHFOs) during hippocampal depth electrode and scalp EEG in patients with MCI and AD; and 3) investigate the effects of brivaracetam on cognition in an open-label pilot study.
Interventions
- DRUG Brivaracetam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2026-01-01 |
| Est. Completion | 2029-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05899764
The ClinicalTrials.gov registry entry for NCT05899764 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Brivaracetam is the first listed.
NCT05899764 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05899764 about?
NCT05899764 is a clinical study titled "Epileptic Hippocampus in Alzheimer's Disease". The major goals of the study are to 1) characterize hippocampal activity in patients with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and AD who have suspected hippocampal epileptic activity based on scalp EEG recordings from IRB # 21-001603; 2) study the efficacy of brivaracetam...
What is the current status of trial NCT05899764?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2026-01-01. Estimated completion is 2029-06-01.
What interventions are being tested in trial NCT05899764?
The interventions under investigation include: Brivaracetam (DRUG).
Who is sponsoring clinical trial NCT05899764?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.